SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The R&D Cost of a New Medicine
0 references·5 citing·19 second hop
The R&D Cost of a New Medicine (2012)The R&D Cost of a New MedicineImproving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology (2015)Improving clinical trials for…Analytical models for biopharmaceutical operations and supply chain management: a survey of research literature (2015)Analytical models for biophar…Orphan drugs policies: a suitable case for treatment (2014)Orphan drugs policies: a suit…Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (2014)Incremental cost per quality-…A decade of innovation in pharmaceutical R&D: the Chorus model (2014)A decade of innovation in pha…A theory of justice original editionCost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Economic Modeling Considerations for Rare Diseases (2018)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)The Oxford Handbook of Regulation (2010)Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force (2011)Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation (2015)Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries (2016)HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries (2017)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Measuring the effectiveness and impact of an open innovation platform (2017)Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity (2021)Designing and Managing the Supply Chain (2002)The price of innovation: new estimates of drug development costs (2003)Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency (2009)Deaths: final data for 2010. (2013)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2014Orphan drugs policies: a suitable case for treatment84 cited
  • 2014A decade of innovation in pharmaceutical R&D: the Chorus model81 cited
  • 2015Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology76 cited
  • 2014Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders73 cited
  • 2015Analytical models for biopharmaceutical operations and supply chain management: a survey of research literature15 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work